Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
By Mahesh Yadav, S. Jhunjhunwala, Q. Phung, P. Lupardus, Josh Tanguay, Stephanie M Bumbaca, C. Franci, Tommy K. Cheung, J. Fritsche, T. Weinschenk and 4 more. Nature, 2014
1,155 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/26bfd968d6c8e125f0db453a3d60c4a2c7bd52f0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Kristen E. Pauken
- E. Wherry
- D. Pardoll
- Janis Taube
- Timothy A. Chan
- Christopher Sander
- Ming O. Li
- Rafi Ahmed
In Molecular Biology
- S. Baylin
- Dmitry Avtonomov
- L. Diaz
- Bert Vogelstein
- Kenneth W. Kinzler
- Victor E. Velculescu
- Andy T. Kong
- Dattatreya Mellacheruvu
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Microsatellite Instability as a Biomarker for PD-1 Blockade (2016, background): “These approaches, and others not yet utilized in clinical settings (14), have significant promise, but they rely on whole-exome sequencing of tumor samples followed by extensive bioinformatic analysis, an approach not yet practical for routine diagnostic use.”
- Overcoming T cell exhaustion in infection and cancer (2015, background): “For example, for tumors with little or no infiltrating immune cells, perhaps vaccination will induce activation of the anti-tumor adaptive immune response and trafficking to the tumor [120, 123].”
- Neoantigens: promising targets for cancer therapy (2023, background): “Nevertheless, low TMB can produce neoantigen-reactive lymphocytes in hematological malignancies and certain epithelial cancers, such as gastrointestinal cancers.(10,240,478) The insufficient neoantigen density in malignancies with low TMB, such as AML and pediatric brain cancers, requires greater po”
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “A higher number of tumor mutations is expected to result in greater numbers of MHC binding neo-antigens, which have been proposed to drive tumor immune-infiltration and response to immunotherapy [9, 10, 13, 24–26].”
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015, positive): “They support the view that the number and type of alterations may prove to be valuable for judging the potential usefulness of immune checkpoint inhibitors, even in mismatch repair–proficient cancers.(41,48,54) Most importantly, our results show an approach for the treatment of a specific class of t”